Trials / Completed
CompletedNCT00637845
Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease (GERD)
A Multi-centred, Phase IV, Post-Marketing, Prospective, Randomized, Double-Blind Study Comparing Esomeprazole Magnesium 40mg Once Daily Versus Lansoprazole 30 mg Twice Daily in Symptom Control of Subjects With Persistent Gastrooesophageal Reflux Disease While on 30mg Once Daily Lansoprazole Therapy
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 248 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A double-blind study comparing Esomeprazole Magnesium 40 mg once daily and Lansoprazole 30 mg twice daily to control the symptoms in patients with gastroesophageal reflux disease (GERD) with continued heartburn symptoms with a course of therapy of 30 mg twice daily Lansoprazole.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Esomeprazole Magnesium | 40mg once daily |
| DRUG | Lansoprazole | 30mg twice daily |
Timeline
- Start date
- 2002-06-01
- Primary completion
- 2003-02-01
- Completion
- 2003-02-01
- First posted
- 2008-03-18
- Last updated
- 2011-01-21
Source: ClinicalTrials.gov record NCT00637845. Inclusion in this directory is not an endorsement.